KLB Drug Discovery Landscape & Assay Solutions

  • By admin
  • 22 Aug 2026
  • Comments

Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Disease Development.

Target Biology and Key Variants

KLB (β-Klotho) is a single-pass transmembrane protein that functions as an obligate co-receptor for FGF19 and FGF21 signaling. It forms a ternary complex with FGFR1c to mediate metabolic effects in adipose tissue, liver, and pancreas. Key genetic variants in KLB (UniProt Q86Z14) include missense mutations rs34905034 (VAR_061207), rs17618244 (VAR_034053), and rs35372803 (VAR_034054), which may impact receptor function and drug response.

TarMart Solution Ecosystem & Related Targets

Comprehensive reagent toolkit for KLB drug discovery. Select your modality below:

Component / Network Product Description Product Link
Antigen KLB ECD-Fc / Mutant Protein
High purity (>95%), Endotoxin <1EU/ug. Sequence Verified, HEK293 Expressed.		 View KLB Products
Ligand FGF21 Recombinant Protein
Wild-type and analog sequences for ternary complex assays.		 View FGF21 Products
Complex Partner FGFR1c ECD-Fc Fusion Protein
For ternary complex assembly with KLB and FGF21.		 View FGFR1 Products
Gene Delivery KLB Promise-ORF / Lentivirus
Full-length ORF for stable cell lines. Essential for functional cellular assays.		 View KLB Products
Benchmark Ab Anti-KLB (Agonistic Reference)
Recombinant positive control for binding affinity comparisons.		 View KLB Products
Validator KLB siRNA Set
For knockdown verification and specificity checks.		 View KLB Products
Related Target A FGF21
Primary physiological ligand; crucial for evaluating receptor complex activation.		 View FGF21 Products
Related Target B FGFR1
Coreceptor obligate for KLB-mediated signal transduction in adipose tissue.		 View FGFR1 Products
Critical Assay Challenge The TarMart Advantage (Technical Spec)
Ternary Complex Assembly (KLB-FGFR1c-FGF21) Matched pair of ECD-Fc proteins (Human/Mouse/Cyno) with theoretical MW verified by Mass Spec.
Cross-species cyno/mouse eval Human/Mouse/Cyno ortholog proteins available with >95% purity for translational bridging.
Complex Receptor Formation & Internalization Lentivirus reagents for KLB/FGFR1 co-expression stable cell line generation; validated for trafficking studies.
Lack of Controls Clinical Benchmark Antibodies included for reliable standard curves.
False Positives Validated siRNA included for rigorous specificity checks in native cells.

Live KLB R&D Tracker

Market data changes daily. Access the latest global pipeline status directly:

Global Clinical Landscape & Future Outlook

The race for KLB (Klotho Beta) therapeutics is intensifying, driven by the massive unmet need in metabolic disorders, particularly MASH (Metabolic dysfunction-associated steatohepatitis) and obesity. Major players are focused on FGF21 analogs (e.g., Akero Therapeutics, 89bio, Eli Lilly) and direct KLB-targeting antibodies (e.g., Novo Nordisk, Pfizer). As first-generation FGF21 therapies approach late-stage clinical validation, challenges such as patient hypervariability and resistance mechanisms have spurred development of bispecific agonistic antibodies that specifically target the KLB/FGFR1c complex. The next wave of R&D is targeting prolonged half-life formulations and synergistic combinations with incretin mimetics (e.g., GLP-1/GIP) to maximize fat reduction while preserving lean muscle mass.

Competitive Modality & Indication Snapshot

Modality Representative Players Key Indications Critical Assay Need (Why TarMart?)
FGF21 Analogs / Fusions Akero Therapeutics, 89bio, Eli Lilly MASH, Severe Hypertriglyceridemia Binding Kinetics (Need high-purity HEK293-expressed ECD-Fc)
Agonistic mAbs Genentech, NGM Bio Obesity, Type 2 Diabetes Cellular Activation (Need Lentivirus for KLB/FGFR1 cell lines)
Bispecifics (FGFR1/KLB) & Anti-KLB Antibodies Novo Nordisk, Pfizer, Various Biotechs Metabolic Syndromes Heterodimer Validation (Need Cross-reactive ortholog antigens)

Assay Strategy Recommendations

High-quality reagents are critical for robust screening. Key assay strategies include:

  • SPR/BLI using KLB ECD-Fc (high purity, HEK293) to measure binding kinetics.
  • Ternary complex assembly validated via AlphaLISA or similar proximity assays.
  • Cell-based functional assays (pERK, calcium flux) using KLB/FGFR1 co-expressing stable cell lines.
  • Cross-species reactivity panels (human, cynomolgus, mouse) to support translational studies.

TarMart provides all necessary reagents—antigens, lentivirus, benchmark antibodies, and siRNA—to address these challenges with documented quality (>95% purity, <1EU/ug endotoxin, sequence verified).